Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.5505
-0.0545-9.01%
Volume:42.41K
Turnover:24.39K
Market Cap:6.93M
PE:-0.59
High:0.6080
Open:0.6080
Low:0.5501
Close:0.6050
52wk High:1.69
52wk Low:0.5480
Shares:12.59M
Float Shares:7.91M
Volume Ratio:0.99
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9400
EPS(LYR):-1.9269
ROE:-46.15%
ROA:-27.73%
PB:0.18
PE(LYR):-0.29

Loading ...

Aprea Therapeutics shareholders elect three Class I directors at annual meeting

Reuters
·
Jun 18

Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026

Reuters
·
Jun 01

Aprea Therapeutics - Files for Resale of up to 5.5 Mln Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
May 16

Aprea Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Aprea Therapeutics Q1 net loss narrows as R&D expenses fall

Reuters
·
May 13

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 13

Aprea Therapeutics Q1 EPS USD -0.22

THOMSON REUTERS
·
May 13

Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data

Dow Jones
·
May 13

Top News Today/Canada: Pet Valu Trims Outlook Amid Squeezed Margins

Dow Jones
·
May 13

Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
May 08

Aprea Therapeutics, Inc. :  Oppenheimer Initiates Coverage With Outperform Rating and Target Price $5

THOMSON REUTERS
·
May 07

Aprea Therapeutics files to sell 74.35M shares of common stock for holders

TIPRANKS
·
Apr 23

Aprea to present early Phase 1 data for WEE1 inhibitor APR-1051 at ASCO 2026

Reuters
·
Apr 21

Aprea Therapeutics to Provide Clinical Update on Acesot-1051 Phase 1 Trial Evaluating Wee1 Inhibitor, Apr-1051, at Asco 2026 Annual Meeting

THOMSON REUTERS
·
Apr 21

Aprea Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 20